NOW APPROVED for pediatric patients 10 years of age and older with type 2 diabetes as an adjunct to diet and exercise to improve glycemic control1. See the data
Mounjaro: The #1 most prescribed branded T2D medication for adults in the U.S.1
Branded = a pharmaceutical product that is marketed under a proprietary name by the firm that created it. ||| caption
Prescribed = both prescribed and filled based on prescription data for both new and refill prescriptions (total) in the U.S. as of 7/4/2025. ||| caption
Data based on IQVIA® APLD Claims Data accessed on 8/15/2025.1 ||| caption
Mounjaro is the first in a new class for the treatment of T2D1
The first and only GIP and GLP-1 receptor agonist indicated to improve glycemic control in adults with type 2 diabetes. ||| h4
GIP=glucose-dependent insulinotropic polypeptide; GLP-1=glucagon-like peptide-1; APLD=anonymized patient level data.
Mounjaro works differently1
A single molecule that activates the GIP and GLP-1 receptors in the body.1
Select Important Safety Information
Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin: Concomitant use with an insulin secretagogue (e.g., sulfonylurea) or insulin may increase the risk of hypoglycemia, including severe hypoglycemia. The risk of hypoglycemia may be lowered by reducing the dose of sulfonylurea (or other concomitantly administered insulin secretagogue) or insulin. Inform patients using these concomitant medications of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia.
Superior A1C reduction across clinical trials1*
* Across the five phase 3 SURPASS studies in adults, mean reductions in A1C with Mounjaro ranged from 1.8% to 2.1% for the 5-mg dose, 1.7% to 2.4% for the 10-mg dose, and 1.7% to 2.4% for the 15-mg dose; and for comparators, 0.1% and 0.9% for placebo, 1.9% for Ozempic® 1 mg, 1.3% for Tresiba®, and 1.4% for insulin glargine. p<0.05 for superiority vs. study comparators, adjusted for multiplicity.1
Unmatched weight results across clinical trials1†
Mounjaro is not indicated for weight loss. Change in weight was a secondary endpoint.
† Across the five phase 3 SURPASS studies in adults, mean reductions in body weight ranged from 12 lb to 17 lb for the 5-mg dose, 15 lb to 21 lb for the 10-mg dose, and 17 lb to 25 lb for the 15-mg dose; and for comparators, mean change was -2 lb and +4 lb for placebo, +4 lb for Tresiba®, +4 lb for insulin glargine, and -13 lb for Ozempic® 1 mg. p<0.05 for superiority of Mounjaro vs study comparators, adjusted for multiplicity.1
Select Important Safety Information
https://main--ewi-mounjaro-aem-us--elilillyco.aem.page/fragments/sisi/warning-thyroid-c-cell-tumor
Reference:
- Data on File. DOF-TR-US-0062. Lilly USA, LLC.